IGF-1 DES (Des(1-3)IGF-I) — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

IGF-1 DES (Des(1-3)IGF-I)

Also known as: Des(1-3)IGF-I, Des(1-3) IGF-1, truncated IGF-I, IGF-1 des, des-N-(1-3)-IGF-1

Truncated IGF-1 analog / growth factor peptide

Research chemicalLast updated: October 31, 2026Based on 14 peer-reviewed studies

What it is

IGF-1 DES is a modified form of the natural growth factor IGF-1 that people use for muscle growth and recovery, believed to act more potently in local tissue. It's also studied in animal models for neuroprotection and gut development. Not approved for human use; prohibited by WADA; sold as a black-market research compound.

The scientific side

Des(1-3)IGF-I is a naturally occurring truncated variant of human IGF-1 formed by post-translational cleavage that removes the N-terminal tripeptide Gly-Pro-Glu (GPE) from position 1–3 of the mature IGF-1 sequence. The absence of glutamate at position 3 markedly reduces its affinity for IGF-binding proteins (IGFBPs), resulting in approximately 10-fold greater potency than full-length IGF-1 at stimulating hypertrophy and proliferation of cultured cells, because more free peptide is available to engage the type 1 IGF receptor (IGF-1R). Like full-length IGF-1, Des(1-3)IGF-I signals through IGF-1R, activating downstream PI3K/Akt and MAPK/ERK pathways to promote cell growth, survival, and differentiation (PMID 10750042, PMID 11145572). Because IGFBPs do not effectively sequester it, its biological activity is less modulated by circulating binding proteins compared to native IGF-1 (PMID 8930132, PMID 9389554, PMID 11145572). In vivo, selective anabolic effects are particularly evident in gut tissues, and it retains mitogenic, pro-survival, and anti-apoptotic properties.

Class: Truncated IGF-1 analog / growth factor peptide

Administration & storage

Administration
Intramuscular injection (animal studyrats; PMID: 33587816)In vitro direct addition to cell culture / organ culture medium (PMID: 7779409PMID: 10750042PMID: 8940346PMID: 12573816)
Storage
No storage conditions for des(1-3)IGF-I are described in the reviewed literature. Abundant signs of lower quality, including oxidized peptide forms, were found in black market products of IGF-I analogs.
Cautions
Never approved for use in humans; available on the black market as a bodybuilding product with documented quality issues including oxidized peptide forms.,Classified as a prohibited substance in sport by WADA; use carries regulatory and legal risk.,Markedly reduced IGFBP affinity means normal circulating IGFBP buffering mechanisms do not modulate its activity, potentially resulting in unpredictable tissue exposure compared to native IGF-1.,Demonstrated potent mitogenic activity in prostate epithelial and BPH stromal cells in preclinical models; potential oncogenic risk has not been evaluated in humans (PMID: 18026134, PMID: 12573816).,No human pharmacokinetic, safety, or dosing data exist in the reviewed literature — all dosing information derives from animal or in vitro studies only.,Sterile technique is essential for any injectable compound to prevent infection; this is a general harm-reduction principle.

Legal & regulatory status

US FDA

Not approved for human use. Described in reviewed literature as a black market product available for bodybuilding and never approved for use in humans.

WADA

Prohibited substance in sport per reviewed literature

Health Canada

Not stated in reviewed literature — requires manual verification